Dietary consideration and protease inhibitors. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Dietary consideration and protease inhibitors. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

STEP Perspect. 1996 Fall;8(3):11-4. Unique Identifier : AIDSLINE AIDS/97702553
Lichtenstein BS


Abstract: Protease inhibitor therapy requires that the patient have adequate liver function in order to detoxify the substance before it reaches toxic levels in the bloodstream. Liver functioning is described, as well as the effects of several drugs. Ritonavir, for example, inactivates the cP450 enzyme, which retards the liver's ability to filter out antihistamines and antidepressants, causing life-threatening levels. A healthy diet and avoidance of alcohol and tobacco products can help promote optimum liver functioning. Also, caffeine and cola should be used in limited quantities by those on protease inhibitor therapy.
Keywords: Alcohol Drinking/ADVERSE EFFECTS Cytochrome P-450/DRUG EFFECTS/*METABOLISM HIV Infections/*DIET THERAPY/*DRUG THERAPY HIV Protease Inhibitors/ADVERSE EFFECTS/*METABOLISM Human Hydrocarbons/ADVERSE EFFECTS Liver/*METABOLISM Ritonavir/ADVERSE EFFECTS/*METABOLISM Smoking/ADVERSE EFFECTS NEWSLETTER ARTICLEKWDalcoholdrinking/adverseeffectscytochromep-450/drugeffects/KWDmetabolismhivinfections/KWDdiettherapy/KWDdrugtherapyhivproteaseinhibitors/adverseeffects/KWDmetabolismhumanhydrocarbons/adverseeffectsliver/KWDmetabolismritonavir/adverseeffects/KWDmetabolismsmoking/adverseeffectsnewsletterarticle
970830
M9781198

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .